Octapharma's Balfaxar, a prothrombin complex concentrate, has received FDA approval for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy. The product demonstrated effective hemostasis in 94.6% of patients and was non-inferior to comparator Kcentra.
A recent study published in the Journal of Clinical Immunology suggests that cutaquig infusions at higher infusion rates and volumes are well-tolerated and effective, with reduced infusion time, fewer injection sites, and improved compliance. The study results will be presented at the Clinical Immunology Society 2023 Annual Meeting.
The Octapharma USA grant supports the Immunoglobulin National Society's breakfast symposium on PANS/PANDAS, a subset of pediatric acute-onset neuropsychiatric syndrome associated with strep. The program will focus on diagnosis criteria, pathogenic mechanisms, and current treatment options for challenging cases.
A new cutaquig study found that increasing infusion volume per site resulted in a reduction of injection sites, while increasing infusion rates decreased infusion duration. The research also showed that dosing every other week demonstrated equivalency to trough levels with weekly dosing.
Wilate prophylaxis showed an 84% reduction in bleeding episodes and improved quality of life in children and adults with all types of VWD. The treatment reduced the frequency of bleeding episodes by lowering the mean total annualized bleeding rate compared to on-demand treatment.
A large randomized clinical trial demonstrated Octagam 10% as an efficacious and well-tolerated treatment option for adult dermatomyositis patients. The study showed improved outcomes in patients with this rare disease, providing a much-needed treatment alternative.
The FDA has granted orphan drug status to Octagam 10%, the first and only IVIg treatment for adult dermatomyositis. The therapy is expected to become the first treatment option for adults with this rare disease, which affects approximately 10 out of every million U.S. residents.
The FDA has approved Octagam 10% for treating adult dermatomyositis, a rare immune-mediated inflammatory disease. The approval is based on positive results of the ProDERM study, which showed significant improvement in patient response to treatment.
The FDA has approved supplements to biological license applications for Octaplas and fibryga, strengthening Octapharma USA's pediatric critical care product portfolio. The new labels provide results from post-marketing studies evaluating the products' efficacy, safety, and tolerability in newborns through age 20. Fibryga's indication i...
Researchers evaluated the efficacy and safety of fibryga, Octaplas, and Octaplex in treating congenital and acquired bleeding disorders. Fibryga demonstrated efficacy in on-demand treatment and perioperative prophylaxis for patients with rare congenital fibrinogen deficiency.
A study by Octapharma at ASH found that high-dose Octagam 10% IVIg significantly improved hypoxia and reduced hospital length of stay in COVID-19 patients with pneumonia. A larger multicenter study is underway to determine if the therapy can slow or stop respiratory deterioration.
Two new posters will present investigative treatment options using NUWIQ and WILATE for rare bleeding disorders. The research focuses on long-term prophylaxis with Simoctocog Alfa for hemophilia A, as well as the use of a von Willebrand Factor/Coagulation Factor VIII Complex for treatment of inherited platelet disorders.
Researchers aim to enroll patients aged 6-17 with moderate to severe PANS and evaluate the effectiveness of PANZYGA versus placebo in reducing symptoms. The study will also assess sustainability and functional impairment associated with PANS treatment.
Researchers are investigating the use of intravenous immunoglobulin (IVIG) to treat COVID-19 patients experiencing respiratory failure. Preliminary data show promise in preventing mechanical ventilation and improving outcomes for critically ill patients.
The FDA approved a phase 3 clinical trial to evaluate the efficacy and safety of high-dose Octagam 10% therapy in COVID-19 patients with severe disease progression. The study aims to determine if IVIG can slow or stop respiratory deterioration in these patients.
Researchers discussed recent clinical study results comparing fibrinogen concentrate and cryoprecipitate in cardiac surgery, highlighting fibryga as a potential alternative for managing perioperative bleeding. The studies provide important data on fibryga's efficacy and safety in treating acquired fibrinogen deficiency.
Rutgers University chemists have developed a patent-pending HER catalyst Ni5P4 that has the potential to replace platinum in electrolyzers and fuel cells, lowering material costs while maintaining efficiency. The researchers aim to test the compound's operating stability and efficiency over extended time periods in commercial devices.
Researchers at Rutgers University have developed a platform called NanoScript, which can interact with endogenous DNA and regulate gene expression. This technology has great potential for advancing stem cell therapeutics and treating debilitating injuries and diseases such as Parkinson's disease and spinal cord trauma.